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Social impact 
Breast cancer is one of the leading causes of cancer death among women world-
wide.  The Dutch breast cancer screening program, established to detect (early 
stage) breast cancer, has seen a recall rate of 2-3%. Approximately 70% of these 
recalls prove to be false positives.  
 Radiological abnormalities that later prove erroneous engender unnecessary 
anxiety and needless follow-up testing, which in turn generates unnecessary health 
care costs. Rapid clarification to establish a final diagnosis is especially important 
in the work-up of these patients. 
Relevance of this thesis  
In this thesis, our aim was to demonstrate that Contrast enhanced spectral mam-
mography (CESM) is feasible and safe in clinical practice. We also assessed image 
quality and evaluated if this new technique did not come at the expense of unac-
ceptable radiation exposure. Our research therefore focused on women recalled 
from the breast screening program who underwent CESM as part of their clinical 
work-up. CESM was found to be superior to conventional digital mammography 
despite the relatively low disease prevalence in this population. However, breast 
cancer CESM is not an option because the radiation dose still exceeds that of 
mammography, and CESM requires intravenous administration of iodine-based 
contrast agents.  
 
Currently, Dutch women recalled from the screening program are informed by 
their general practitioner and referred to a breast cancer clinic of their choice for 
further analysis. Due to existing waiting lists a delay of several days is common 
before the patient is seen by a nurse practitioner or surgeon, who then refers the 
patient to the Radiology department for further imaging and/or biopsy. Since re-
call is based on the detection of a radiological abnormality one might consider 
changing the approach in order to shorten the diagnostic pathway. This could be 
achieved through direct referral to an (expert breast-) radiologist who could rapid-
ly discriminate between benign lesions (such as superposition or cyst) and lesions 
that need further work-up. 
 
As discussed in this thesis, the use of CESM not only allows for more accurate 
breast cancer detection than conventional mammography, but also for more confi-
dent detection of false positive recalls. This could abolish the need for mammo-
graphic follow-ups after six, twelve or even eighteen months. In addition, CESM 
technique has the potential to replace breast MRI in preoperative assessment.  
 
Rapid access and implementation of an ‘intermediate stage’ between screening and 
referral to a breast clinic. The results of this thesis advocate such an approach in 
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which CESM plays a significant role. This could have several potential benefits: (1) 
less interval cancers due to the higher diagnostic accuracy of CESM as compared to 
conventional mammography; (2) reduced patient anxiety due to rapid access and 
confident diagnosis of false positive recalls; and (3) reduction in health care costs 
due to the absence of unnecessary downstream testing. 
Target groups 
The results of this thesis may be of interest to radiologists, radiology departments, 
breast care clinics and last but not least, the patients themselves. 
 When using CESM, diagnostic accuracy will increase regardless of radiologist 
experience.  CESM can therefore be introduced without any significant learning 
curves. In addition, CESM provides potential downstream benefits such as the 
avoidance of more time-consuming, invasive or costly tests (e.g. ultrasound, MRI or 
biopsies). From a technical perspective, most (modern digital) mammography 
units can be upgraded to include CESM technology; no additional equipment is 
required (although an automated injector is recommended for standardized intra-
venous contrast delivery).’ 
 
In addition to its use as problem-solving modality for women recalled from the 
breast screening program, CESM has numerous other potential indications such as 
inconclusive full-field digital mammography findings, neoadjuvant chemotherapy 
response monitoring, high risk patient screening, breast-conserving therapy eval-
uation, and unknown primary tumour evaluation, which are currently all breast 
MRI indications. Since breast MRI is not widely available in most countries even in 
Europe, upgrading existing mammography units with CESM could improve the 
diagnostic imaging chain. Furthermore, CESM might serve as an excellent alterna-
tive where contraindications for breast MRI exist (obesity, claustrophobia, metal 
implants, etc.).  
 
Primary use of CESM in breast care clinics can reduce the number of false positives 
referred from cancer screening. This would lead to an increased cancer prevalence 
in the recall population visiting the breast cancer clinics, enabling a focus shift 
from ruling out suspected malignancy to (true) breast cancers. A CESM-based 
work-up would also reduce the number of short-term follow-up lesions (so called 
BI-RADS 3), and accelerate the diagnostic pathway, frequently rendering breast 
MRI superfluous.  
 
An advantage for patients is the increased specificity of CESM which will reduce 
the number of recalls, and since CESM is a straightforward imaging method, early 
access would reduce recall-patient anxiety. CESM was originally developed as an 
aid in the detection of breast cancer in women with dense breast tissue, and there-
fore, it could be of great interest for patients with dense breasts.  
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Even though CESM is a rather novel modality in the field of breast imaging, studies 
showing its strong potential and clinical relevance are being published in rapid 
succession, resulting in an increased number of units being installed worldwide. 
Over the next few years CESM is expected to become accepted as one of the stand-
ard breast imaging modalities, offering immediate solutions for a relevant clinical 
and social problem.  
  
